查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018748

乳癌诊断市场：依技术、产品、生物标记、检体类型和最终用户划分－2026-2032年全球市场预测

Breast Cancer Diagnostics Market by Technology, Product, Biomarker, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，乳癌诊断市场价值将达到 76 亿美元，到 2026 年将成长到 82 亿美元，到 2032 年将达到 130.6 亿美元，复合年增长率为 8.04%。

主要市场统计数据
基准年 2025 76亿美元
预计年份：2026年 82亿美元
预测年份 2032 130.6亿美元
复合年增长率 (%) 8.04%

概述不断发展的乳癌诊断市场，重点关注临床效用和营运转型之间的交集。

乳癌诊断正经历快速变革时期，主要得益于检体采集技术、检体分析、影像技术和分子谱分析技术的同步发展。新的工具正在重塑从初步筛检到最终诊断和治疗分层的临床路径，而放射科、病理科和分子检查室之间的跨学科合作对于实现精准医疗也变得日益重要。更丰富的资料流，包括数位乳房断层合成影像、用于演算法审查的数位化免疫组化切片以及基于次世代定序的基因组特征，正在增强临床决策能力，这既为医疗服务提供者和产业带来了机会，也带来了挑战。

影像、组织取样、病理自动化和分子分析技术的进步正在系统地重新定义诊断过程和临床工作流程。

多项变革正在改变乳癌的检测、分类和后续观察方式。首先，影像技术正从类比影像转向以数位影像为主的模式，透过磁振造影（MRI）和超音波，以及数位乳房断层合成和先进的乳房X光摄影，增强病灶的表征和分诊。这些影像技术越来越多地与电脑工具结合，辅助放射科医生解读影像并确定切片检查的优先顺序。其次，切片检查方法也日趋多样化。针刺活检和手术技术的改进，在最大限度保留组织的同时，实现了更全面的后续检查，从而影响了检查室的工作流程和耗材需求。

2025 年美国关税环境对诊断供应链、筹资策略和临床获得先进检测的实际影响。

美国2025年实施的关税政策和贸易措施为诊断设备和试剂的供应链带来了巨大摩擦。进口关税及相关合规要求推高了部分设备和耗材的成本，影响了采购计划，并促使一些检查室和医院重新评估其供应商多元化策略。为此，采购团队日益重视确保本地库存，并加强合约条款以降低关税波动带来的风险。同时，製造商也正在探索国内生产和近岸外包，以减少跨境关税的影响。

从技术架构、产品系列、生物标记、检体类型和最终用户需求等方面获取可操作的细分洞察，以指导优先排序。

了解市场区隔对于使产品开发和商业化与临床需求和购买行为相符至关重要。技术细分揭示了切片检查、组织病理学、影像学和分子诊断领域的清晰趋势。针刺活检和手术切片检查的需求各不相同，这两种方法都会影响检体的完整性以及与下游检测的兼容性。组织病理学工作流程分为免疫组织化学和染色系统，每种系统都需要相应的试剂组合和自动化选项。数位乳房断层合成、乳房X光摄影、磁振造影和超音波等影像学方法在筛检和诊断流程中占据不同的位置，从而影响相应的资本投入和培训。分子诊断包括萤光原位杂交（FISH）、基于PCR的方法和次世代定序（NGS），但靶向NGS和全基因测序对数据分析和检查室基础设施的需求不同，而基于PCR的方法又根据灵敏度和处理能力分为数字PCR和即时PCR。

美洲、欧洲、中东和非洲以及亚太地区的区域需求和实施差异决定了临床应用和商业策略。

区域趋势正在影响全球的技术应用、监管流程和报销机制。在美洲，健全的临床研究网络和医院系统为先进影像和分子诊断平台的快速普及提供了支持，而供应链挑战和政策转变则影响着采购行为。在欧洲和中东及非洲，情况更为复杂。在西欧市场，数位病理学和综合生物标记检测的整合领先，而在该地区的新兴市场，基础设施和准入限制使得成本效益高且可靠的诊断方法成为优先考虑因素。监管协调和跨境合作的努力正在逐步加快创新从研究到实用化的进程。

竞争定位、伙伴关係和临床检验如何重新定义乳癌诊断技术和服务提供领域的领导地位。

乳癌诊断领域的竞争格局呈现出传统仪器製造商、新兴分子诊断专家以及来自数位医疗领域的新进参与企业的局面。老牌製造商持续投资于影像系统、切片检查设备和组织病理学仪器的渐进式创新，而新晋参与企业则专注于小众分子检测、靶向测序平台和软体主导的诊断工具。随着各公司努力将硬体功能与分析软体和资讯服务结合，以提供端到端的诊断解决方案，策略伙伴关係和共同开发契约也变得越来越普遍。

为製造商、临床领导者和保险公司提供实际有效的建议，以加速临床部署，同时确保营运弹性。

产业领导者应优先考虑兼顾临床影响和营运扩充性的投资。首先，製造商需要加快影像平台、实验室设备和分子分析的整合，建构一个可互通的生态系统，从而简化临床医生的工作流程并减少交接环节。其次，透过预测性维护、培训和数据驱动的咨询来改善服务模式，可以提高客户维繫并降低医疗保健采购方的整体拥有成本。第三，企业应建构模组化产品线，以便在不中断医院和检查室核心临床服务的情况下，分阶段进行升级和添加新功能。

一个强大的混合方法研究框架，结合了初步临床发现、监管分析和工作流程映射，以支援战略诊断情报。

本研究整合了同行评审文献、监管指导文件、临床试验註册数据以及对临床实验室技术人员、病理学家、放射科医生和采购经理的访谈，从而构建了一个全面的诊断环境分析框架。定量数据和定性见解的交叉检验确保了对技术成熟度、临床效用和商业性可行性的平衡解释。调查方法特别强调绘製切片检查、组织病理学、影像学和分子诊断的工作流程图，以识别瓶颈和整合机会，同时也检验了耗材、设备和软体服务的产品生命週期，以了解售后市场趋势。

融合诊断模式的策略概述及将创新转化为临床影响所需的营运前提

总之，乳癌诊断领域正朝着影像学、组织学分析和分子谱分析更紧密融合的方向发展，并辅以软体和服务，实现数据驱动的临床决策。这些融合模式为提高诊断准确性、实现个人化治疗选择和优化诊疗路径创造了机会，但也需要健全的营运规划和超越临床专科的协作模式。投资于互通性、临床有效性检验和在地化商业性模式的相关人员，将更有能力将技术潜力转化为可衡量的患者获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章乳癌诊断市场：依技术划分

  • 切片检查
    • 针刺切片
    • 手术切片检查
  • 组织病理学
    • 免疫组织化学
    • 染色系统
  • 诊断影像
    • 数位乳房断层合成
    • 乳房X光检查
    • MRI
    • 超音波
  • 分子诊断
    • FISH
    • NGS
      • 标靶NGS
      • 全基因组定序
    • 基于PCR的
      • 数位PCR
      • 即时PCR

第九章乳癌诊断市场：依产品划分

  • 消耗品
    • 试剂和试剂盒
    • 玻片和染色试剂
  • 装置
    • 切片检查装置
    • 组织病理学设备
    • 影像系统
    • 序列器
  • 软体和服务
    • 咨询和维护
    • 数据分析软体

第十章：以生物标记分類的乳癌诊断市场

  • BRCA
  • ER/PR
  • HER2
  • Ki-67

第十一章检体类型分類的乳癌诊断市场

  • 血
  • 血清
  • 组织

第十二章乳癌诊断市场：依最终用户划分

  • 癌症研究中心
  • 诊断检查室
  • 医院
  • 专科诊所

第十三章乳癌诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章乳癌诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章乳癌诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国乳癌诊断市场

第十七章：中国乳癌诊断市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 4D Path Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix
  • Cardinal Health
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc. by Cell Microsystems
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Paragon Biosciences LLC by Catalent, Inc.
  • Provista Diagnostics, Inc. by Todos Medical
  • Quest Diagnostics Incorporated
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market was valued at USD 7.60 billion in 2025 and is projected to grow to USD 8.20 billion in 2026, with a CAGR of 8.04%, reaching USD 13.06 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.60 billion
Estimated Year [2026] USD 8.20 billion
Forecast Year [2032] USD 13.06 billion
CAGR (%) 8.04%

A concise orientation to the evolving breast cancer diagnostics landscape highlighting crossroads between clinical utility and operational transformation

Breast cancer diagnostics are undergoing a period of rapid transformation driven by parallel advances in sampling techniques, tissue analytics, imaging technologies, and molecular profiling. Emerging tools are reshaping clinical pathways from initial screening through definitive diagnosis and therapeutic stratification, while multidisciplinary collaboration between radiology, pathology, and molecular laboratories is increasingly essential to deliver precision care. Clinical decision-making is being augmented by richer data streams, including digital breast tomosynthesis images, immunohistochemistry slides digitized for algorithmic review, and genomic signatures from next-generation sequencing, all of which create both opportunity and complexity for providers and industry.

Against this backdrop, stakeholders must reconcile operational constraints with evolving standards of care. Adoption dynamics differ across end users such as cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, and they are influenced by product segmentation spanning consumables, instruments, and software and services. Sample type considerations, whether blood, serum, or tissue, will continue to dictate workflow design and specimen logistics. In sum, the diagnostic landscape requires integrated strategic planning that balances clinical utility, workflow efficiency, and sustainable reimbursement pathways.

How advances in imaging, tissue sampling, histopathology automation, and molecular profiling are systematically redefining diagnostic pathways and clinical workflows

Several transformative shifts are changing how breast cancer is detected, classified, and monitored. First, imaging is moving from analogue to digital-first ecosystems, where digital breast tomosynthesis and advanced mammography are complemented by MRI and ultrasound to enhance lesion characterization and triage. These imaging modalities are increasingly integrated with computational tools that augment radiologist interpretation and prioritize cases for biopsy. Second, biopsy approaches are diversifying as needle and surgical techniques are refined to maximize tissue preservation while enabling comprehensive downstream testing, which in turn affects laboratory workflows and consumable demand.

Meanwhile, histopathology is evolving through greater adoption of immunohistochemistry and automated staining systems that increase throughput and reproducibility. Molecular diagnostics are also rising in clinical prominence; fluorescence in situ hybridization, PCR variants, and next-generation sequencing, including targeted panels and whole genome approaches, are delivering granular biomarker insights that drive therapeutic decisions. Complementing these technological shifts are new service models around data analysis software and consulting that support interpretation, quality control, and integration with electronic medical records. Collectively, these trends are reshaping procurement priorities, clinical pathways, and partnerships across the diagnostic ecosystem.

Practical implications of the United States tariff environment in 2025 on diagnostic supply chains, procurement strategies, and clinical access to advanced testing

Tariff policies and trade measures in the United States for 2025 have introduced practical friction into the supply chains that underpin diagnostic device and reagent availability. Import duties and related compliance requirements have elevated the cost of certain instruments and consumables, affecting procurement timelines and prompting some laboratories and hospitals to reassess supplier diversification strategies. In response, procurement teams are increasingly emphasizing localized inventory buffers and contractual clauses that mitigate tariff volatility, while manufacturers are evaluating onshore production and nearshoring to reduce exposure to cross-border tariff impacts.

As a result of these shifts, commercial strategies are adapting to preserve continuity of care and maintain access to critical testing modalities such as sequencers, imaging systems, and specialized staining reagents. Manufacturers and distributors are negotiating revised reseller agreements and exploring collaborative consignment models to stabilize supply. For clinical leaders, the tariff environment underscores the importance of supply chain resilience planning and scenario-based budgeting that account for regulatory and trade-driven costs, without compromising diagnostic quality or patient access to timely testing.

Actionable segmentation insights across technology architectures, product portfolios, biomarkers, sample types, and end-user demands to guide prioritization

Understanding market segmentation is essential to align product development and commercialization with clinical needs and purchasing behavior. Technology segmentation reveals distinct dynamics across biopsy, histopathology, imaging, and molecular diagnostics. Biopsy demand is differentiated by needle and surgical approaches, each influencing sample integrity and downstream assay compatibility. Histopathology workflows are bifurcated by immunohistochemistry and staining systems that require tailored reagent portfolios and automation options. Imaging modalities including digital breast tomosynthesis, mammography, MRI, and ultrasound are being positioned differently across screening and diagnostic pathways, with implications for capital investment and training. Molecular diagnostics encompass FISH, PCR-based methods, and next-generation sequencing, where targeted NGS and whole genome sequencing create divergent demands for data analysis and laboratory infrastructure, and PCR-based approaches split between digital PCR and real-time PCR in terms of sensitivity and throughput.

Product segmentation further delineates responsibilities across consumables, instruments, and software and services. Consumables such as reagents and slides have recurring revenue profiles and logistics sensitivities, whereas instruments-ranging from biopsy devices and histopathology instruments to imaging systems and sequencers-require long-term service and upgrade strategies. Software and services, including consulting, maintenance, and data analysis platforms, are increasingly important to extract clinical value from complex datasets. Biomarker segmentation, spanning BRCA, ER/PR, HER2, and Ki-67, dictates assay development priorities and informs clinical utility claims for companion diagnostics. Sample type considerations-blood, serum, and tissue-impact pre-analytical workflows, stability protocols, and the selection of appropriate molecular or imaging approaches. Finally, end user segmentation, covering cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, highlights the need for adaptable solutions that can scale from research-grade assays to high-throughput clinical diagnostics.

Regional imperatives and adoption differentials across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical adoption and commercial strategy

Regional dynamics shape technology adoption, regulatory pathways, and reimbursement practices across the globe. In the Americas, strong clinical research networks and hospital systems are supporting rapid uptake of advanced imaging and molecular diagnostic platforms, while supply chain considerations and policy shifts are influencing procurement behavior. Europe, the Middle East & Africa present a heterogeneous picture: Western European markets often lead in integrating digital pathology and comprehensive biomarker testing, while emerging markets in the region face infrastructure and access constraints that prioritize cost-effective and robust diagnostic modalities. Regulatory harmonization efforts and cross-border collaborations are gradually altering the pace at which innovations move from research to practice.

In the Asia-Pacific region, rapid infrastructure development and significant investments in healthcare technology are accelerating adoption of high-throughput molecular tools and imaging solutions, with an emphasis on scalability and localized manufacturing. Across all regions, differences in reimbursement frameworks, workforce capacity, and centralized versus decentralized laboratory models are the primary determinants of technology diffusion. Consequently, commercial strategies must be regionally nuanced, balancing standardized global value propositions with tailored implementations that reflect local clinical workflows and regulatory expectations.

How competitive positioning, partnerships, and clinical validation are redefining leadership in breast cancer diagnostic technologies and service delivery

Competitive dynamics in breast cancer diagnostics are defined by a mix of legacy instrument providers, emerging molecular specialists, and digital health entrants. Incumbent manufacturers continue to invest in incremental innovation for imaging systems, biopsy devices, and histopathology instrumentation, while newer entrants focus on niche molecular assays, targeted sequencing panels, and software-driven interpretation tools. Strategic partnerships and co-development agreements are increasingly common as companies seek to pair hardware capabilities with analytic software and data services to deliver end-to-end diagnostic solutions.

Moreover, consolidation through targeted acquisition of niche technology providers and alliances with clinical networks is reshaping go-to-market strategies. Strong aftermarket services and training programs are differentiating suppliers, especially for complex instruments that require ongoing maintenance and validation. Access to high-quality, curated clinical datasets and the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence are essential competitive advantages. Ultimately, companies that can integrate robust clinical validation, scalable manufacturing, and responsive commercial support will be best positioned to capture long-term engagement with hospitals, laboratories, and specialized clinics.

Practical, high-impact recommendations for manufacturers, clinical leaders, and payers to accelerate clinical adoption while safeguarding operational resilience

Industry leaders should prioritize investments that align clinical impact with operational scalability. First, manufacturers should accelerate integration between imaging platforms, laboratory instrumentation, and molecular analytics to create interoperable ecosystems that simplify clinician workflows and reduce handoffs. Second, enhancing service models-through predictive maintenance, training, and data-driven consulting-will increase customer retention and lower the total cost of ownership for institutional buyers. Third, companies should build modular product offerings that allow hospitals and laboratories to phase upgrades and add capabilities without disrupting core clinical services.

From a clinical perspective, stakeholders must emphasize assay standardization and cross-disciplinary training to ensure consistent interpretation of imaging and molecular results. Supply chain diversification and localized inventory strategies can mitigate tariff and trade risk while preserving access to critical consumables and instruments. Finally, payers and health systems should be engaged early to define value-based reimbursement pathways that recognize the downstream benefits of precise diagnostics, including reduced overtreatment and improved therapy matching. Taken together, these measures will enable sustainable adoption and maximize the clinical utility of emerging diagnostic innovations.

A robust mixed-methods research framework combining primary clinical insights, regulatory analysis, and workflow mapping to underpin strategic diagnostics intelligence

This research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and primary interviews with clinical laboratorians, pathologists, radiologists, and procurement leaders to create a holistic diagnostic landscape analysis. Quantitative inputs were triangulated with qualitative insights to ensure balanced interpretation of technology readiness, clinical utility, and commercial feasibility. The methodology placed particular emphasis on workflow mapping across biopsy, histopathology, imaging, and molecular diagnostics to identify bottlenecks and integration opportunities, and it examined product life cycles for consumables, instruments, and software-enabled services to understand aftermarket dynamics.

Data quality was assured through cross-validation of technical specifications, regulatory clearances, and device labeling, coupled with expert validation sessions to confirm clinical relevance. Regional analyses incorporated regulatory frameworks and reimbursement paradigms across the Americas, Europe, Middle East & Africa, and Asia-Pacific to reflect diverse adoption scenarios. Where possible, findings were corroborated with case studies and implementation examples to ground strategic recommendations in operational reality.

A strategic summation of converging diagnostic modalities and the operational prerequisites needed to translate innovation into clinical impact

In conclusion, the breast cancer diagnostics field is moving toward tighter integration of imaging, tissue-based analyses, and molecular profiling, supported by software and services that enable data-driven clinical decisions. These converging modalities are creating opportunities to refine diagnostic accuracy, personalize treatment selection, and streamline care pathways, but they also necessitate robust operational planning and collaborative models across clinical specialties. Stakeholders that invest in interoperability, clinical validation, and regionally adapted commercial approaches will be best positioned to translate technological promise into measurable patient benefit.

Looking forward, resilience in supply chains, agility in regulatory strategy, and demonstrable value to payers will be critical enablers of sustainable adoption. By aligning product roadmaps with real-world clinical workflows and by engaging early with end users and payers, diagnostic innovators and health systems can accelerate the adoption of high-value technologies while maintaining equitable access to timely and accurate breast cancer diagnosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Diagnostics Market, by Technology

  • 8.1. Biopsy
    • 8.1.1. Needle Biopsy
    • 8.1.2. Surgical Biopsy
  • 8.2. Histopathology
    • 8.2.1. Immunohistochemistry
    • 8.2.2. Staining Systems
  • 8.3. Imaging
    • 8.3.1. Digital Breast Tomosynthesis
    • 8.3.2. Mammography
    • 8.3.3. MRI
    • 8.3.4. Ultrasound
  • 8.4. Molecular Diagnostics
    • 8.4.1. FISH
    • 8.4.2. NGS
      • 8.4.2.1. Targeted NGS
      • 8.4.2.2. Whole Genome Sequencing
    • 8.4.3. PCR-Based
      • 8.4.3.1. Digital PCR
      • 8.4.3.2. Real-Time PCR

9. Breast Cancer Diagnostics Market, by Product

  • 9.1. Consumables
    • 9.1.1. Reagents And Kits
    • 9.1.2. Slides And Staining Reagents
  • 9.2. Instruments
    • 9.2.1. Biopsy Devices
    • 9.2.2. Histopathology Instruments
    • 9.2.3. Imaging Systems
    • 9.2.4. Sequencers
  • 9.3. Software And Services
    • 9.3.1. Consulting And Maintenance
    • 9.3.2. Data Analysis Software

10. Breast Cancer Diagnostics Market, by Biomarker

  • 10.1. BRCA
  • 10.2. ER/PR
  • 10.3. HER2
  • 10.4. Ki-67

11. Breast Cancer Diagnostics Market, by Sample Type

  • 11.1. Blood
  • 11.2. Serum
  • 11.3. Tissue

12. Breast Cancer Diagnostics Market, by End User

  • 12.1. Cancer Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialized Clinics

13. Breast Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Breast Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Breast Cancer Diagnostics Market

17. China Breast Cancer Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 4D Path Inc.
  • 18.6. Abbott Laboratories
  • 18.7. Agilent Technologies, Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Becton, Dickinson and Company
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Biocept, Inc.
  • 18.12. Biodesix
  • 18.13. Cardinal Health
  • 18.14. Danaher Corporation
  • 18.15. Epigenomics AG
  • 18.16. Exact Sciences Corporation
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. Fluxion Biosciences Inc. by Cell Microsystems
  • 18.19. FUJIFILM Holdings Corporation
  • 18.20. General Electric Company
  • 18.21. Hologic, Inc.
  • 18.22. Illumina, Inc.
  • 18.23. Koninklijke Philips N.V.
  • 18.24. NanoString Technologies, Inc.
  • 18.25. NeoGenomics Laboratories
  • 18.26. Olea Medical
  • 18.27. OncoGenomX
  • 18.28. Paragon Biosciences LLC by Catalent, Inc.
  • 18.29. Provista Diagnostics, Inc. by Todos Medical
  • 18.30. Quest Diagnostics Incorporated
  • 18.31. Siemens Healthcare Private Limited
  • 18.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 289. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS BREAST CANCER DIAGNOSTICS